2C-B-ButterFLY, also known as 2C-B-BFLY or as 2C-B-MOTH, is a serotonin receptor modulator of the phenethylamine, 2C, and FLY families. It is a conformationally-restricted derivative of the psychedelic drug 2C-B and a ring-expanded homologue of the better-known compound 2C-B-FLY.
The properties and effects of 2C-B-ButterFLY in humans do not appear to be known.
2C-B-ButterFLY has similar properties as an agonist for serotonin receptors, but with more selectivity for 5-HT<sub>2C</sub> over 5-HT<sub>2A</sub>.
Analogues of 2C-B-ButterFLY include 2C-B, 2C-B-FLY, 2C-B-DragonFLY, DOB-FLY, and Bromo-DragonFLY (DOB-DFLY), among others.
2C-B-ButterFLY was discovered by Michael S. Whiteside and Aaron Monte in 1999.
2C-B-ButterFLY is a controlled substance in Canada under 2C blanket-ban language.
2C-B-ButterFLY is illegal in Latvia.
2C-B-ButterFLY is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.